Breast Cancer Gene Panel Predicts Chemotherapy Response

Key Highlights

• Researchers at The University of Texas MD Anderson Cancer Center identified macrophage subtypes linked to chemotherapy response in triple-negative breast cancer (TNBC).
• A 13-gene transcriptional signature and machine learning model may help predict which patients respond better to neoadjuvant chemotherapy.
• The study analyzed more than 427,000 cells from 101 TNBC patients using single-cell and spatial transcriptomic technologies.
• Findings published in Nature could support future precision oncology strategies in breast cancer care.
• For More Updates on Breast Cancer and women’s health, register for #HerHealth2026

How a 13-Gene Panel Could Improve Triple-Negative Breast Cancer Treatment

Triple-negative breast cancer (TNBC) remains one of the most aggressive and difficult-to-treat forms of breast cancer, often showing unpredictable responses to chemotherapy. Researchers from The University of Texas MD Anderson Cancer Center have now identified a promising 13-gene panel capable of predicting chemotherapy response in patients with early-stage TNBC.

The study, led by Nicholas Navin and Clinton Yam, offers one of the most comprehensive single-cell genomic analyses conducted in TNBC to date. Published in Nature, the findings provide new insight into how tumor cells and immune cells interact inside the tumor microenvironment (TME).

TNBC lacks estrogen, progesterone, and HER2 receptors, limiting targeted treatment options and making chemotherapy the primary standard of care. However, clinicians frequently observe major differences in treatment response between patients. Researchers aimed to determine the biological mechanisms responsible for this variability.

Using pre-treatment tumor tissue samples, investigators analyzed over 427,000 cells from 101 patients and compared the findings with healthy breast tissue data from the Human Breast Cell Atlas. Advanced single-cell sequencing and spatial transcriptomics enabled researchers to classify TNBC tumors into four distinct archetypes based on cancer-cell gene expression patterns.

Macrophage Subtypes Show Strong Link to Chemotherapy Response

One of the study’s most clinically relevant findings involved macrophages, immune cells traditionally associated with inflammatory and anti-tumor responses. While earlier TNBC studies primarily focused on T cells, this research highlighted distinct macrophage subtypes strongly associated with either favorable or poor chemotherapy outcomes.

Researchers also identified 49 immune cell states forming eight structured cellular neighborhoods within the TME. These immune landscapes appeared closely connected to the tumor archetypes and treatment response patterns.

The resulting 13-gene transcriptional signature became the foundation for a machine learning model designed to predict chemotherapy sensitivity before treatment begins. Investigators believe this approach could eventually help oncologists personalize neoadjuvant chemotherapy strategies and reduce unnecessary toxicity for patients unlikely to benefit from standard regimens.

What This Means for Precision Oncology and Breast Cancer Care

The findings represent a significant step toward more individualized treatment planning in TNBC. Predictive biomarker panels combined with machine learning could improve clinical decision-making and help identify patients who may benefit from alternative therapies or future immunotherapy combinations.

Although additional prospective validation studies are still required before clinical implementation, the research strengthens growing evidence that the tumor microenvironment plays a central role in chemotherapy response.

Explore All Oncology CME Conferences and Online Courses 2026

For oncologists, oncology nurses, and cancer researchers, the study reinforces the importance of integrating genomic profiling, immune-cell characterization, and AI-driven predictive models into future breast cancer management strategies.

Source:

University of Texas M. D. Anderson Cancer Center